Ph.D. Dinesh V Patel - 23 Jan 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
President and CEO, Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.
Issuer symbol
PTGX
Transactions as of
23 Jan 2026
Net transactions value
-$3,543,112
Form type
4
Filing time
27 Jan 2026, 21:21:26 UTC
Previous filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PATEL DINESH V PH D President and CEO, Director C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK /s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D. 27 Jan 2026 0001120477

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Gift $0 -6,000 -1% $0.000000 574,505 23 Jan 2026 Direct F1
transaction PTGX Common Stock Options Exercise $81,316 +19,315 +3.4% $4.21 593,820 23 Jan 2026 Direct
transaction PTGX Common Stock Sale $1,633,856 -19,315 -3.3% $84.59 574,505 23 Jan 2026 Direct F2
transaction PTGX Common Stock Options Exercise $44,984 +10,685 +1.9% $4.21 585,190 26 Jan 2026 Direct
transaction PTGX Common Stock Sale $897,540 -10,685 -1.8% $84.00 574,505 26 Jan 2026 Direct F3
transaction PTGX Common Stock Options Exercise $306,544 +14,205 +2.5% $21.58 588,710 26 Jan 2026 Direct
transaction PTGX Common Stock Sale $1,193,930 -14,205 -2.4% $84.05 574,505 26 Jan 2026 Direct F4
transaction PTGX Common Stock Options Exercise $87,787 +4,068 +0.71% $21.58 578,573 27 Jan 2026 Direct
transaction PTGX Common Stock Sale $338,417 -4,068 -0.7% $83.19 574,505 27 Jan 2026 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -19,315 -64% $0.000000 10,685 23 Jan 2026 Common Stock 19,315 $4.21 Direct F6
transaction PTGX Stock Option (right to buy) Options Exercise $0 -10,685 -100% $0.000000 0 26 Jan 2026 Common Stock 10,685 $4.21 Direct F6
transaction PTGX Stock Option (right to buy) Options Exercise $0 -14,205 -4.5% $0.000000 304,068 26 Jan 2026 Common Stock 14,205 $21.58 Direct F7
transaction PTGX Stock Option (right to buy) Options Exercise $0 -4,068 -1.3% $0.000000 300,000 27 Jan 2026 Common Stock 4,068 $21.58 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 23, 2026, the Reporting Person made a charitable donation of 6,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes.
F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84.41 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.095. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.075. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.06 to $83.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6 These stock options are fully vested and will expire on April 29, 2026.
F7 These stock options are fully vested and will expire on October 11, 2026.